Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10616642 | 0.91 | MEN1 (0.41) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL9266164 | 0.91 | MEN1 (0.41) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL30736446 | 0.88 | MEN1 (0.41) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL3190037 | 0.88 | ALDH1A1 (0.43) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL1185918 | 0.86 | ALDH1A1 (0.44) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL30958584 | 0.86 | ALDH1A1 (0.44) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL8877353 | 0.86 | GAA (0.41) | MEN1KMT2AALDH1A1GAAGPR35 | |
| SCHEMBL4468897 | 0.86 | KMT2A (0.40) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10618493 | 0.85 | KMT2A (0.39) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10630773 | 0.84 | MEN1 (0.40) | MEN1KMT2AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61205240-A | — | — | None | — | — | JP | disclosed |
| CN-122036535-A | Antibacterial sitafloxacin preparation method of star intermediate | 惠州信立泰药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-113527262-B | Refining method of delafloxacin and meglumine salt thereof | 安徽普利药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-113527262-A | Refining method of delafloxacin and meglumine salt thereof | 安徽普利药业有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| CN-105294648-B | A kind of preparation method of sitafloxacin | 山东罗欣药业集团股份有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-103360310-B | The preparation method of a kind of Sitafloxacin intermediate, Sitafloxacin and sitafloxacin medicine composition | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-104876911-A | Simple method for synthesizing delafloxacin | NANJING UNIVERSITY OF TECHNOLOGY | 2015-09-02 | — | — | CN | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-0341493-A2 | Optically active pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4880814-A | 7-cycloalkyl naphthyridines | ABBOTT LABORATORIES (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0183129-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-08-09 | — | — | EP | disclosed |
| US-4767762-A | Tricyclic quinoline and naphthyride antibacterials | ABBOTT LABORATORIES (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0275971-A1 | Process and intermediates for quinolonecaboxylic acid | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-07-27 | — | — | EP | disclosed |
| EP-0227088-A1 | Isoxazolo-naphthyridine, isoxazolo quinoline, isothiazolonaphthyridine, and isothiazoloquinoline derivatives | ABBOTT LABORATORIES (US) | 1987-07-01 | — | — | EP | disclosed |
| EP-0195841-A1 | Quinolinecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-10-01 | — | — | EP | disclosed |
| EP-0195316-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-09-24 | — | — | EP | disclosed |
| JP-S61205240-A | BENZOYLACETIC ESTER DERIVATIVE | KYORIN PHARMACEUT CO LTD | 1986-09-11 | — | — | JP | disclosed |
| EP-0183129-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | MEN1 1468/4885KMT2A 2161/4885KDM4E 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.